These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37476323)

  • 1. Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study.
    Ogilvie AC; Schultz JL
    Mov Disord Clin Pract; 2023 Jul; 10(7):1120-1125. PubMed ID: 37476323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of antidepressants on depressive symptoms in manifest Huntington's disease.
    Ogilvie AC; Carnahan RM; Chrischilles EA; Schultz JL
    J Psychosom Res; 2022 Nov; 162():111023. PubMed ID: 36063627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.
    Beister A; Kraus P; Kuhn W; Dose M; Weindl A; Gerlach M
    J Neural Transm Suppl; 2004; (68):117-22. PubMed ID: 15354397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clustering and prediction of disease progression trajectories in Huntington's disease: An analysis of Enroll-HD data using a machine learning approach.
    Ko J; Furby H; Ma X; Long JD; Lu XY; Slowiejko D; Gandhy R
    Front Neurol; 2022; 13():1034269. PubMed ID: 36793800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding HD Psychosis: An Analysis from the ENROLL-HD Database.
    Jaini A; Yomtoob J; Yeh C; Bega D
    Tremor Other Hyperkinet Mov (N Y); 2020 Jul; 10():16. PubMed ID: 32775030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent cognitive trajectories in early stage Huntington's disease: A 3-year longitudinal study.
    Martínez-Horta S; Perez-Perez J; Oltra-Cucarella J; Sampedro F; Horta-Barba A; Puig-Davi A; Pagonabarraga J; Kulisevsky J
    Eur J Neurol; 2023 Jul; 30(7):1871-1879. PubMed ID: 36994811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of neurocognitive disorder in Huntington's disease using the Enroll-HD dataset.
    Sierra LA; Ullman CJ; Baselga-Garriga C; Pandeya SR; Frank SA; Laganiere S
    Front Neurol; 2023; 14():1198145. PubMed ID: 37521291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery.
    Prins S; Borghans L; de Kam ML; Groeneveld GJ; van Gerven J
    J Neurol Sci; 2023 Jun; 449():120658. PubMed ID: 37079973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer's Disease-like Pathology.
    Świetlik D; Kusiak A; Krasny M; Białowąs J
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects.
    Davis MY; Keene CD; Jayadev S; Bird T
    J Huntingtons Dis; 2014; 3(2):209-17. PubMed ID: 25062863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal thickness as a biomarker of cognitive impairment in manifest Huntington's disease.
    Murueta-Goyena A; Del Pino R; Acera M; Teijeira-Portas S; Romero D; Ayala U; Fernández-Valle T; Tijero B; Gabilondo I; Gómez Esteban JC
    J Neurol; 2023 Aug; 270(8):3821-3829. PubMed ID: 37079031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia.
    Gareri P; Cotroneo AM; Orsitto G; Putignano S
    Arch Gerontol Geriatr; 2020; 89():104073. PubMed ID: 32447126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington's Disease.
    Achenbach J; Matusch A; Elmenhorst D; Bauer A; Saft C
    Biomedicines; 2022 May; 10(6):. PubMed ID: 35740281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex Differences in Huntington's Disease: Evaluating the Enroll-HD Database.
    Hentosh S; Zhu L; Patino J; Furr JW; Rocha NP; Furr Stimming E
    Mov Disord Clin Pract; 2021 Apr; 8(3):420-426. PubMed ID: 33816672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.